Skip to main content
Erschienen in: PharmacoEconomics 8/2013

01.08.2013 | Review Article

Overview of Parametric Survival Analysis for Health-Economic Applications

verfasst von: K. Jack Ishak, Noemi Kreif, Agnes Benedict, Noemi Muszbek

Erschienen in: PharmacoEconomics | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Health economic models rely on data from trials to project the risk of events (e.g., death) over time beyond the span of the available data. Parametric survival analysis methods can be applied to identify an appropriate statistical model for the observed data, which can then be extrapolated to derive a complete time-to-event curve. This paper describes the properties of the most commonly used statistical distributions as a basis for these models and describes an objective process of identifying the most suitable parametric distribution in a given dataset. The approach can be applied with both individual-patient data as well as with survival probabilities derived from published Kaplan–Meier curves. Both are illustrated with analyses of overall survival from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol trial.
Fußnoten
1
This topic is also covered in a report titled “Extrapolating clinical time-to-event outcomes” for the MRC Methodology Project on Extrapolation of RCT Evidence involving Sheffield University.
 
Literatur
1.
Zurück zum Zitat Cuzick J, Sestak I, Baum M, et al, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–1141. Cuzick J, Sestak I, Baum M, et al, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–1141.
2.
Zurück zum Zitat Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42:2867–75.CrossRefPubMed Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42:2867–75.CrossRefPubMed
3.
Zurück zum Zitat Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23(4):323–32.CrossRefPubMed Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23(4):323–32.CrossRefPubMed
4.
Zurück zum Zitat Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. 2011. http://www.nicedsu.org.uk. Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. 2011. http://​www.​nicedsu.​org.​uk.
5.
Zurück zum Zitat Collett D. Modelling survival data in medical research. 2nd ed. London: Chapman & Hall/CRC; 2003. Collett D. Modelling survival data in medical research. 2nd ed. London: Chapman & Hall/CRC; 2003.
6.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefPubMed
7.
Zurück zum Zitat Kleinbaum DG, Klein M. Survival analysis: a self-learning text. Berlin: Springer; 2005. Kleinbaum DG, Klein M. Survival analysis: a self-learning text. Berlin: Springer; 2005.
8.
Zurück zum Zitat Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–81.CrossRef
9.
Zurück zum Zitat Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill; 1956. p. 75–83. Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill; 1956. p. 75–83.
10.
Zurück zum Zitat Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat Methodol. 1972;34(2):187–220. Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat Methodol. 1972;34(2):187–220.
11.
Zurück zum Zitat Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.CrossRefPubMed Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.CrossRefPubMed
12.
Zurück zum Zitat Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.CrossRefPubMed Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.CrossRefPubMed
13.
Zurück zum Zitat StataCorp LP. STATA survival analysis and epidemiological tables. Reference manual, release 12. College Station: Stata Press; 2011. StataCorp LP. STATA survival analysis and epidemiological tables. Reference manual, release 12. College Station: Stata Press; 2011.
14.
Zurück zum Zitat Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi:10.1186/1471-2288-12-9.CrossRefPubMed Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi:10.​1186/​1471-2288-12-9.CrossRefPubMed
15.
Zurück zum Zitat Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health. 2004;7(5):627–35.CrossRefPubMed Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health. 2004;7(5):627–35.CrossRefPubMed
16.
Zurück zum Zitat Bebbington M, Lai CD, Zitikis R. Modeling human mortality using mixtures of bathtub shaped failure distributions. J Theor Biol. 2007;245(3):528–38.CrossRefPubMed Bebbington M, Lai CD, Zitikis R. Modeling human mortality using mixtures of bathtub shaped failure distributions. J Theor Biol. 2007;245(3):528–38.CrossRefPubMed
17.
Zurück zum Zitat Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Statist Assn. 1992;87(420):942–951. Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Statist Assn. 1992;87(420):942–951.
18.
Zurück zum Zitat Royston P, Parmar MKB. Flexible parametric-hazards and proportional odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175–97.CrossRefPubMed Royston P, Parmar MKB. Flexible parametric-hazards and proportional odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175–97.CrossRefPubMed
19.
Zurück zum Zitat Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–90. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–90.
20.
Zurück zum Zitat Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):article 34. Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):article 34.
21.
Zurück zum Zitat Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172:383–404.CrossRefPubMed Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172:383–404.CrossRefPubMed
22.
Zurück zum Zitat Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak KJ, Ross P. Modeling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28(7):1141–53.CrossRefPubMed Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak KJ, Ross P. Modeling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28(7):1141–53.CrossRefPubMed
23.
Zurück zum Zitat Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082–9.CrossRefPubMed Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082–9.CrossRefPubMed
24.
Zurück zum Zitat Castelli C, Combescure C, Foucher Y, et al. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Stat Med. 2007;26(30):5557–71.CrossRefPubMed Castelli C, Combescure C, Foucher Y, et al. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Stat Med. 2007;26(30):5557–71.CrossRefPubMed
25.
Zurück zum Zitat Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559–66.CrossRefPubMed Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559–66.CrossRefPubMed
26.
Zurück zum Zitat Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–97.CrossRefPubMed Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–97.CrossRefPubMed
27.
Zurück zum Zitat Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12(15):ii–ix, xi–162. Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12(15):ii–ix, xi–162.
28.
Zurück zum Zitat Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14(2):1–184, iii–iv. Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14(2):1–184, iii–iv.
29.
Zurück zum Zitat Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii–iv, ix–221. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii–iv, ix–221.
Metadaten
Titel
Overview of Parametric Survival Analysis for Health-Economic Applications
verfasst von
K. Jack Ishak
Noemi Kreif
Agnes Benedict
Noemi Muszbek
Publikationsdatum
01.08.2013
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 8/2013
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0064-3

Weitere Artikel der Ausgabe 8/2013

PharmacoEconomics 8/2013 Zur Ausgabe

Original Research Article

A Choice That Matters?